Neonatal complications of preterm premature rupture of membranes. Pathophysiology and management.
H W Kilbride, D W Thibeault
https://pubmed.ncbi.nlm.nih.gov/11817188Actively Recruiting
Led by Woman's · Updated on 2021-01-11
34
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying the effect of outpatient oral antibiotics on the length of pregnancy after premature rupture of membranes (water bag rupture) between 18 0/7 weeks and 22 6/7 weeks gestation. This trial compares how long pregnancy continues with or without antibiotic treatment, focusing on patients without other pregnancy complications. The study aims to see if antibiotics influence the time until delivery and the number of patients reaching 23 0/7 weeks gestation. Participants are admitted for a 24-hour hospital observation to ensure no infections or labor signs. Then, they are randomly assigned to receive either a 7-day course of oral antibiotics (azithromycin and amoxicillin) or no antibiotics. The first antibiotic dose is given in the hospital to monitor side effects. Both groups have weekly outpatient follow-up visits with specialists and will be admitted to the hospital at 23 weeks or earlier if complications arise. Upon readmission at 23 weeks, all receive standard medications and care for fetal and maternal health. During the study, participants have regular exams including ultrasounds, blood tests, and vital sign monitoring. They track symptoms and temperature daily, and adherence to antibiotics is checked by pill counts. The main outcome measured is the latency period, or how long pregnancy continues after membrane rupture, which can range from less than one day up to 112 days. Researchers also monitor how many patients reach 23 weeks. Safety is closely observed, and the study lasts until delivery or complications occur.
CONDITIONS
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 24 hours
Participants are admitted for a 24-hour hospital observation period to monitor for signs of infection, preterm labor, or other complications before enrollment and randomization.
Continuous in-hospital monitoring during observation period
Duration - Up to 5 to 7 days of outpatient antibiotic therapy before 23 weeks gestation (for antibiotic arm)
Participants are randomized to receive either antibiotics (azithromycin and amoxicillin) or no antibiotics prior to discharge. Those in the antibiotic arm receive the first dose in the hospital and continue outpatient antibiotic therapy. Both groups receive counseling and a patient information pamphlet.
1 hospital visit for initial dose and discharge, then weekly outpatient visits until 23 weeks gestation
Duration - Up to 5 weeks (from enrollment to 23 0/7 weeks gestation)
Participants attend weekly outpatient follow-up visits with Maternal-Fetal Medicine specialists to monitor maternal and fetal well-being until 23 0/7 weeks gestation or clinical change.
Weekly outpatient visits including vital signs, physical exams, ultrasounds, and lab tests
Duration - From 23 0/7 weeks gestation until delivery (variable duration)
At 23 0/7 weeks gestation, participants are readmitted for inpatient management including fetal neuroprotective treatment, corticosteroids, antibiotics, and close monitoring until delivery.
Continuous inpatient care with regular ultrasounds and fetal monitoring
Total: 1 location
1
Woman's Hospital
Baton Rouge, Louisiana, United States, 70817
Actively Recruiting
F
Felicia LeMoine, MD
R
Robert C Moore, MD
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
H W Kilbride, D W Thibeault
https://pubmed.ncbi.nlm.nih.gov/11817188J D Yeast
https://pubmed.ncbi.nlm.nih.gov/11758532B M Mercer, M Miodovnik, G R Thurnau...
https://pubmed.ncbi.nlm.nih.gov/9307346Brian M Mercer, Robert L Goldenberg, Anita F Das...
https://pubmed.ncbi.nlm.nih.gov/12889589American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine
https://pubmed.ncbi.nlm.nih.gov/28937572Lex W Doyle, Caroline A Crowther, Philippa Middleton...
https://pubmed.ncbi.nlm.nih.gov/19160238B M Mercer, L G Crocker, N M Boe...
https://pubmed.ncbi.nlm.nih.gov/8238131F F Broekhuizen, M Gilman, P R Hamilton
https://pubmed.ncbi.nlm.nih.gov/2410839D B Cotton, L M Hill, H T Strassner...
https://pubmed.ncbi.nlm.nih.gov/6691016